pharmaceutical industry
New STOA study on better access to medicines in the EU
Interview with study author Simona Gamba When it comes to less profitable markets such as rare diseases, paediatric diseases or antimicrobials, medicines in the EU could be hard to come by, both in terms of price and availability. On Thursday 19 October, Senior Assistant Professor Simona Gamba (University of Milan, Italy) presented the study "Improving ...
EU Project : EU-ToxRisk
EU-ToxRisk is an Integrated European ‘Flagship’ Programme Driving Mechanism-based Toxicity Testing and Risk Assessment for the 21st century. The vision of this project is to drive the required paradigm shift in toxicological testing away from ‘black box’ animal testing towards a toxicological assessment based on human cell responses and a comprehensive mechanistic understanding of cause-consequence ...
A scientist’s opinion : Interview with Aroon Hingorani about re-engineering pharmaceutical research
Interview with Aroon Hingorani, Professor of Genetic Epidemiology at University College London about Re-engineering pharmaceutical research. Could you speculate what you think are the biggest causes of drug failure? Aroon Hingorani: It is well recognised that the number one cause for drug failure is a lack of efficacy of the drug in the intended indication, ...
A scientist’s opinion : Interview with Dr Denis Lacombe about re-engineering pharmaceutical research
Interview with Dr Denis Lacombe, Director General of the European Organisation for Research and Treatment of Cancer (EORTC) about Re-engineering pharmaceutical research. Can you tell me a bit about the European Organisation for Research and Treatment of Cancer (EORTC)? Denis Lacombe: We are a non-governmental, not-for-profit organisation established for 60 years, focusing on survival and ...
Re-engineering pharmaceutical research for better patient outcomes
A so-called ‘productivity crisis’ has been ascribed to the pharmaceutical research and development industry. Despite increases in investment and funding, this has not corresponded to increases in the approval of novel drugs. Why do so many drugs fail to receive approval, and what other means should we be focusing on for the benefit of patients?
A scientist’s opinion : Interview with Dr Síle Lane about re-engineering pharmaceutical research
Interview with Dr Síle Lane, head of international campaigns and policy at Sense About Science, about Re-engineering pharmaceutical research. Undisclosed clinical trial results are unfortunately common - how does this impact progression in research and treatment? Síle Lane: When results from clinical trials aren’t published it means the same research can get repeated unnecessarily. This ...